Browse everything: Tickers A–Z · Issuers · Comparisons · Tags
RLAY Stock — Relay Therapeutics, Inc.
Relay Therapeutics, Inc. (RLAY)
Updated October 16, 2026.
RLAY is a Stock. Total return is -53.6% over the past 6.3 years, 212.6 points behind SPY at 159.0%.
Relay Therapeutics is a clinical-stage precision medicines company developing small molecule drugs focused on targeted oncology and genetic diseases, with lead candidates including RLY-2608 (a PI3K alpha inhibitor in clinical development for breast cancer and solid tumors) and programs for Fabry disease and RAS-driven cancers, supported by collaborations with Pfizer, Elevar Therapeutics, and D. E. Shaw Research. The company does not currently distribute to shareholders. This security appeals to investors seeking exposure to early-stage biopharmaceutical development with potential for significant long-term appreciation, though with correspondingly higher risk typical of pre-revenue clinical-stage companies.
RLAY performance versus SPY
Price and return data through 2026-10-16.
Total return is -53.6% over the past 6.3 years, 212.6 points behind SPY at 159.0%. Over the past year its total return — price change plus distributions reinvested — is 150.1%. Its deepest 1-year drawdown was 28.2%.
| Window | Total return | CAGR |
|---|---|---|
| 1M | -13.6% | — |
| 3M | -15.9% | — |
| 6M | 1.1% | — |
| YTD | 92.4% | — |
| 1Y | 150.1% | — |
| 2Y CAGR | — | 54.80% |
| 3Y CAGR | — | 32.90% |
| 5Y CAGR | — | -13.70% |
| Since inception (6.3 years) | -53.6% | -11.50% |
RLAY key facts
- Asset type
- Stock
- Asset class
- Equity
- Inception date
- 07/16/2020
- Distribution frequency
- None
- Last close
- $16.28 (as of 2026-10-16)
- Market cap
- $3,567,625,753
- Average volume
- 2366617.0
- Beta
- 1.731
- Payout ratio
- 0.0%
- EPS
- $-1.53
How Dividend Vision calculates yield and returns
Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.
Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology
Sources and review
Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.
Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.
RLAY risks and drawbacks
Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 28.2%.
Who may consider RLAY — and who may not
It is a weaker fit for investors who need monthly cash flow (RLAY does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.
More on RLAY
Frequently asked questions
Does RLAY pay monthly?
No. RLAY does not currently distribute.
When does RLAY pay a dividend?
RLAY does not currently distribute.
How has RLAY performed?
Total return is -53.6% over the past 6.3 years, 212.6 points behind SPY at 159.0%. Over the past year its total return — price change plus distributions reinvested — is 150.1%. Its deepest 1-year drawdown was 28.2%.
Tickers
Holdings as-of date unavailable.
| Ticker | Name | Weight |
|---|
See how this investment would fit into your portfolio.